EQ - NASDAQ
Equillium, Inc.
$3.15
-1.6%Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
At a Glance
Live SnapshotEquillium, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Equillium, Inc. Income Statement
EQ • NASDAQ
| Equillium, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
130K | 41.1M | 36.1M | 15.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||
(65K) | (0.0) | (0.0) | (0.0) | (0.0) | (45K) | (23K) | (6.1K) | (122.0) | |
65K | 41.1M | 36.1M | 15.8M | 0.0 | -45K | -23K | -6.1K | -122.0 | |
OPERATING INCOME | |||||||||
(23.6M) | (49.4M) | (50.6M) | (77.8M) | (37.8M) | (29.5M) | (26.7M) | (8.6M) | (1.7M) | |
(10.8M) | (11.9M) | (13.6M) | (17.2M) | (11.4M) | (10.1M) | (9.1M) | (3.7M) | (378.2K) | |
(12.8M) | (37.4M) | (37M) | (37.5M) | (26.4M) | (19.4M) | (17.6M) | (4.9M) | (1.3M) | |
-23.6M | -8.3M | -14.5M | -62.1M | -37.8M | -29.5M | -26.7M | -8.6M | -1.7M | |
PRE-TAX INCOME | |||||||||
(0.0) | (0.0) | (491K) | (1.1M) | (1.1M) | (1.1M) | (279K) | (2.6M) | (379.4K) | |
833K | 1.4M | 1.8M | -633K | -1M | -623K | 1.1M | -2.2M | 0.0 | |
(0.0) | (0.0) | (0.0) | (23M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
1.2M | 563K | 1.8M | -352K | -1.3M | -265K | 1.1M | -4.6M | -549.8K | |
-22.4M | -7.7M | -12.8M | -62.4M | -39.1M | -29.8M | -25.6M | -13.3M | -2.3M | |
NET INCOME | |||||||||
(0.0) | (361K) | (580K) | (0.0) | (0.0) | (0.0) | -23K | (140.5K) | -2.0 | |
-22.4M | -8.1M | -13.3M | -62.4M | -39M | -29.8M | -25.6M | -13.3M | -2.3M |
SEC Filings
EQ - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 15, 2026 | May 28, 2026 | 2026 | |
S-3 S-3 N/A | April 07, 2026 | April 07, 2026 | ||
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 13, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
S-3 S-3 N/A | November 13, 2025 | November 13, 2025 |
Related Guides
Continue your EQ research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.